OncoGenex’s OGX-427 drug gaining investor attention
Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second...
View ArticleMicromedic seeking diagnostic partners on multiple fronts
With approvals in Europe and Israel for its CellDetect non-invasive test for recurrence of bladder cancer, Micromedic Technologies (TASE:MCTC) is seeking FDA approval for a pivotal trial expected to...
View ArticleImagin Medical taking bladder cancer imaging to next level
Imagin Medical’s (CSE:IME; OTC:IMEXF) i/Blue Imaging System is expected to improve physicians’ ability to detect bladder cancer with minimally invasive endoscopes and reduce recurrence by dramatically...
View ArticleClik here to view.
Imagin Medical adds world-renowned bladder cancer expert Dr. Ashish Kamat to SAB
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) named Dr. Ashish Kamat to its scientific advisory board. Dr. Kamat has been named by Expertscape as the world’s top-rated...
View ArticleClik here to view.
Imagin Medical updates i/Blue’s functional unit development
Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) provided an update on its progress towards verifying the i/Blue imaging system’s functional prototype. The company has...
View ArticleClik here to view.
Theralase in pact for U.S. clinical sites for Phase 2 NMIBC trial
Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) signed an agreement with a trial management organization (TMO) to provide four-to-six U.S.-based urology study sites that will be able to commence...
View ArticleClik here to view.
Theralase Phase 2 NMIBC clinical study could support marketing application
Shawn Shirazi, CEO Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) has designed its Phase 2 clinical study in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) based on FDA...
View Article
